Alirocumab-Associated Lichenoid Reaction: A Case Report

Thumbnail
Identificadores

URI: http://hdl.handle.net/10498/33757

DOI: 10.1016/J.AD.2022.11.022

ISSN: 0001-7310

ISSN: 1578-2190

Ficheros
Estadísticas
Métricas y Citas
 
Compartir
Exportar a
EndNoteBibTexRIS
Metadatos
Mostrar el registro completo del ítem
Título alternativo
Erupción liquenoide asociada al uso de alirocumab: presentación de un caso
Autor/es
Román Cheuque, R.; Navarro Navarro, Irene; Jiménez Gallo, D.; Linares Barrios, Mario DionisioAutoridad UCA
Fecha
2024
Departamento/s
Medicina
Fuente
Actas Dermo-Sifiliograficas - 2024, Vol. 115 n.5 pp. 522-523
Resumen
Lichenoid eruptions (LE) pose a real diagnostic challenge dueto their clinical and histopathological similarity to lichenplanus. Inducers are varied being drug-induced lichenoideruption (DILE) a common entity, particularly in an eracharacterized by the emergence of biologic or targeted ther-apies. This is the case of an alirocumab-induced lichenoideruption, a proprotein convertase subtilisin/kexin type 9(PCSK-9) inhibitor used to treat dyslipidemia, a drug rarelyassociated with local skin adverse reactions and exception-ally with urticaria, or vasculitis.
Materias
Alirocumab; lichenoid eruption
Colecciones
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional